Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Primary care

Building Your Care Team & Long-Term Surveillance

At a Glance

1q21.1 microdeletion syndrome often requires coordinated, long-term care rather than one specialist. A primary care clinician can organize genetics, heart, developmental, neurologic, and mental health services, while age-based monitoring and an up-to-date medical passport support proactive care.

Managing a 1q21.1 microdeletion is a marathon, not a sprint. Because the syndrome is “multisystemic”—meaning it can affect the heart, brain, and growth—no single doctor can provide all the necessary care [1][2]. Instead, you will build a multidisciplinary care team to monitor your health or your child’s health over many years.

The goal of this team is not just to treat problems as they arise, but to stay ahead of them through proactive “surveillance” [2].

Your Core Care Team

While your primary care doctor or pediatrician is the “hub” of your care, you will likely need to see several specialists for baseline evaluations and periodic check-ups:

  • Medical Geneticist & Genetic Counselor: They interpret the microarray report, explain inheritance risks, and help coordinate care with other specialists [2][3].
  • Cardiologist: Since up to 35% of carriers have heart differences, a cardiologist is often recommended to perform a baseline echocardiogram [1][4]. They will determine if repeat imaging is needed based on those initial results.
  • Neurologist: Recommended if there are concerns about seizures (which occur in about 30% of cases), unusual movements, or significant motor delays [4][2].
  • Developmental Pediatrician: Essential for tracking milestones, coordinating early intervention (like speech or physical therapy), and managing school-age concerns like ADHD or learning disabilities [5][4].
  • Psychiatrist or Psychologist: Particularly important as a child reaches adolescence and adulthood to monitor for mood disorders or psychiatric risks [6][7].

A Lifespan Surveillance Framework

Because the symptoms of 1q21.1 can change as a person grows, the focus of medical monitoring shifts over time.

Early Childhood (Ages 0–5)

The focus is on “building the foundation.”

  • Growth and Feeding: Monitoring for poor weight gain or growth faltering (reported in up to 68% of infants) and low muscle tone (hypotonia) [4][5].
  • Therapies: Early enrollment in Physical Therapy (PT), Occupational Therapy (OT), and Speech-Language Pathology (SLP) to address developmental delays [5][4].
  • Baseline Checks: Ensuring the “baseline” heart, kidney, and eye exams discussed on the screening page are completed [1][8].

School Age (Ages 6–12)

The focus shifts to learning and behavior.

  • Educational Support: School-based evaluation or optional private neuropsychological testing to create an Individualized Education Program (IEP) for learning disabilities or ADHD [5][9].
  • Skeletal Health: Regular checks for scoliosis or other spine/joint issues that may emerge during growth spurts [10].

Adolescence and Adulthood (Ages 13+)

The focus turns toward mental health and transition.

  • Psychiatric Monitoring: Age-appropriate screening in primary care for anxiety, depression, or early signs of more serious psychiatric conditions. Specialist surveillance is symptom-driven [6][11].
  • Transition Planning: Preparing the young adult to understand their diagnosis, manage their own medications, and move from pediatric to adult specialists [12].

Organizing Your “Medical Passport”

Because this condition is rare, you may often find yourself “teaching” new doctors about 1q21.1. Keeping a highly organized medical record (a “medical passport”) is essential. Your records should include:

  1. The Original Lab Report: The full Chromosomal Microarray (CMA) report with specific coordinates (e.g., BP3–BP4) and the genome build used (hg19 or hg38) [13][14].
  2. Imaging Reports: Copies of the baseline echocardiogram and renal ultrasound reports.
  3. Growth Charts: A longitudinal record of height, weight, and head circumference over time [4].
  4. Summary of Findings: A one-page “care summary” from your geneticist that lists the primary risks (like the specific warning signs covered in the screening guide) and current medications.

By maintaining these records and a consistent team, you ensure that even as life changes, your care remains focused and proactive [2][15].

Common questions in this guide

Who should be involved in care for 1q21.1 microdeletion syndrome?
A primary care doctor or pediatrician can serve as the medical home and coordinate with a medical geneticist and genetic counselor. Depending on a person’s findings, the team may also include cardiology, neurology, developmental pediatrics, mental health professionals, and physical, occupational, or speech therapists.
What baseline health checks may be recommended for 1q21.1 microdeletion?
Initial monitoring may include an echocardiogram, kidney imaging such as a renal ultrasound, and an eye examination. The cardiologist and other clinicians decide whether and when repeat testing is needed based on the baseline results and the person’s health.
How does 1q21.1 microdeletion surveillance change with age?
In early childhood, visits focus on growth, feeding, muscle tone, milestones, and early therapies. During school years, monitoring emphasizes learning, attention, behavior, and possible spine problems; in adolescence and adulthood, mental health and transition to adult care become more important. The schedule should be individualized rather than assumed to be the same for everyone.
What should be included in a medical passport for 1q21.1 microdeletion?
Keep the complete chromosomal microarray report, including its genomic coordinates and genome build, along with imaging reports, growth charts, and a current care summary. The summary can list important findings, medications, specialist recommendations, and warning signs that another clinician should know.
When might someone with 1q21.1 microdeletion need neurology or mental health support?
Neurology may be helpful when there are seizures, unusual movements, or significant motor delays. Primary care clinicians should monitor for anxiety, depression, or other concerning psychiatric changes and arrange mental health evaluation when symptoms or behavior raise concern.

Get notified when new evidence is published on 1q21.1 microdeletion syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    Phenotypic spectrum of 1q21.1 copy number variants in 42 children: genotype-phenotype correlations and clinical implications.

    Mutlucan Köseoğlu G, Ceylan AC, Çavdarlı B, et al.

    European journal of pediatrics 2026; (185(11)).

    PMID: 42862371
  2. 2

    Phenotypic and genotypic characterization of 1q21.1 copy number variants: A report of 34 new individuals and literature review.

    Bourgois A, Bizaoui V, Colson C, et al.

    American journal of medical genetics. Part A 2024; (194(3)):e63457 doi:10.1002/ajmg.a.63457.

    PMID: 37881147
  3. 3

    Chromosomal Microarray With Clinical Diagnostic Utility in Children With Developmental Delay or Intellectual Disability.

    Lee JS, Hwang H, Kim SY, et al.

    Annals of laboratory medicine 2018; (38(5)):473-480 doi:10.3343/alm.2018.38.5.473.

    PMID: 29797819
  4. 4

    Clinical characterization of individuals with the distal 1q21.1 microdeletion.

    Edwards SD, Schulze KV, Rosenfeld JA, et al.

    American journal of medical genetics. Part A 2021; (185(5)):1388-1398 doi:10.1002/ajmg.a.62104.

    PMID: 33576134
  5. 5

    Clinical phenotype of the recurrent 1q21.1 copy-number variant.

    Bernier R, Steinman KJ, Reilly B, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2016; (18(4)):341-9 doi:10.1038/gim.2015.78.

    PMID: 26066539
  6. 6

    Comparing Copy Number Variations in a Danish Case Cohort of Individuals With Psychiatric Disorders.

    Calle Sánchez X, Helenius D, Bybjerg-Grauholm J, et al.

    JAMA psychiatry 2022; (79(1)):59-69 doi:10.1001/jamapsychiatry.2021.3392.

    PMID: 34817560
  7. 7

    A review on the relationship between the distal 1q21.1 microdeletion and schizophrenia.

    Guo X, Guo J, Liu X, Hu T

    Frontiers in genetics 2025; (16()):1612654 doi:10.3389/fgene.2025.1612654.

    PMID: 40792073
  8. 8

    Five patients with a chromosome 1q21.1 triplication show macrocephaly, increased weight and facial similarities.

    Van Dijck A, van der Werf IM, Reyniers E, et al.

    European journal of medical genetics 2015; (58(10)):503-8.

    PMID: 26327614
  9. 9

    [The Gap between Need and Reality in Neuropsychological Care in Pediatric Oncology - Position Paper].

    Lüttich P, Leiss U, Ross H, et al.

    Klinische Padiatrie 2026; doi:10.1055/a-2880-2057.

    PMID: 42612673
  10. 10

    Interstitial 1q21.1 Microdeletion Is Associated with Severe Skeletal Anomalies, Dysmorphic Face and Moderate Intellectual Disability.

    Gamba BF, Zechi-Ceide RM, Kokitsu-Nakata NM, et al.

    Molecular syndromology 2016; (7(6)):344-348 doi:10.1159/000450971.

    PMID: 27920638
  11. 11

    Recommendations for the surveillance of mental health problems in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

    Marchak JG, Christen S, Mulder RL, et al.

    The Lancet. Oncology 2022; (23(4)):e184-e196 doi:10.1016/S1470-2045(21)00750-6.

    PMID: 35358467
  12. 12

    Healthcare Transition to Adulthood in Patients with 22q11.2 Deletion Syndrome: A Comprehensive Literature Review and Transition Framework.

    MacIsaac MF, Mattia A, Montes LA, et al.

    The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association 2026; (63(5)):1357-1372 doi:10.1177/10556656251331392.

    PMID: 40223294
  13. 13

    The Diagnostic Utility of Prenatal Microarray in High-Risk Pregnancies: A Single-Center Experience in Enhancing Reproductive Care and Risk Stratification.

    Bakır A, Alay MT, Tekbaş UC, et al.

    Diagnostics (Basel, Switzerland) 2025; (15(17)) doi:10.3390/diagnostics15172129.

    PMID: 40941617
  14. 14

    Prenatal diagnosis of the recurrent 1q21.1 microdeletions in fetuses with ultrasound anomalies and review of the literature.

    Liu L, Lei T, Guo F, et al.

    Frontiers in genetics 2024; (15()):1448341 doi:10.3389/fgene.2024.1448341.

    PMID: 39268082
  15. 15

    Prenatal diagnosis of 1q21.1 microdeletions and microduplications: a retrospective case series.

    Liu Z, Yi S, Li M, Liu N

    Molecular cytogenetics 2025; (18(1)):23 doi:10.1186/s13039-025-00731-6.

    PMID: 41029435

This page explains care coordination and long-term surveillance for 1q21.1 microdeletion syndrome for informational purposes only and does not constitute medical advice. Your genetics team and treating specialists can tailor monitoring to your or your child’s findings.